These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Compassionate use of cefiderocol for carbapenem-resistant Mabayoje DA; NicFhogartaigh C; Cherian BP; Tan MGM; Wareham DW JAC Antimicrob Resist; 2021 Jun; 3(Suppl 1):i21-i24. PubMed ID: 34223152 [TBL] [Abstract][Full Text] [Related]
5. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
6. Activity of Cefiderocol Against Iregui A; Khan Z; Landman D; Quale J Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915 [TBL] [Abstract][Full Text] [Related]
7. In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Carcione D; Siracusa C; Sulejmani A; Migliavacca R; Mercato A; Piazza A; Principe L; Clementi N; Mancini N; Leoni V; Intra J Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827247 [TBL] [Abstract][Full Text] [Related]
8. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens. Jorda A; Zeitlinger M Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355 [No Abstract] [Full Text] [Related]
14. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986 [TBL] [Abstract][Full Text] [Related]
15. Cefiderocol-Based Combination Therapy for "Difficult-to-Treat" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives. Bavaro DF; Belati A; Diella L; Stufano M; Romanelli F; Scalone L; Stolfa S; Ronga L; Maurmo L; Dell'Aera M; Mosca A; Dalfino L; Grasso S; Saracino A Antibiotics (Basel); 2021 May; 10(6):. PubMed ID: 34072342 [TBL] [Abstract][Full Text] [Related]
16. [Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections]. Kuai J; Wang X; Wang H Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):990-1003. PubMed ID: 35355469 [TBL] [Abstract][Full Text] [Related]
17. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821 [TBL] [Abstract][Full Text] [Related]
18. Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study. Bleibtreu A; Dortet L; Bonnin RA; Wyplosz B; Sacleux SC; Mihaila L; Dupont H; Junot H; Bunel V; Grall N; Razazi K; Duran C; Tattevin P; Dinh A; The Cefiderocol French Study Group OBO Microorganisms; 2021 Jan; 9(2):. PubMed ID: 33573148 [TBL] [Abstract][Full Text] [Related]
19. Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of Ballesté-Delpierre C; Ramírez Á; Muñoz L; Longshaw C; Roca I; Vila J Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203791 [TBL] [Abstract][Full Text] [Related]
20. Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii. Oliva A; Ceccarelli G; De Angelis M; Sacco F; Miele MC; Mastroianni CM; Venditti M J Glob Antimicrob Resist; 2020 Dec; 23():292-296. PubMed ID: 33065329 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]